Clinical readout
J&J's dual bispecific regimen lowers PSA in most treated prostate cancer patients
Among 15 heavily treated patients in a first-in-human trial, 11 saw PSA fall by at least half on pasritamig plus JNJ-9401, and seven by 90% or more. No grade 3 or worse treatment-related side effects occurred; three patients had mild cytokine release syndrome. The pairing is now being tested in KLK2-comPAS, a phase 3 trial.
- Drugpasritamig
- TargetKallikrein-related peptidase 2
- TargetT cell surface glycoprotein CD3
- TrialNCT06095089
- TrialNCT07164443
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.